Logo

Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer

Share this

Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer

Shots:

  • Following the CHMP’s positive opinion in Apr 2024, the EC has approved Fruzaqla (VEGFR-1, -2 & -3 inhibitor) alone in adults administered with prior standard therapies & progressed on/intolerant to trifluridine-tipiracil or regorafenib. It was approved in the US on Nov 8, 2023
  • The approval was supported by a P-III (FRESCO-2) study assessing Fruzaqla + best supportive care (BSC) vs PBO + BSC in treatment-experienced mCRC adults
  • The study reached all 1EPs & 2EPs, demonstrating consistent benefits & a favorable safety profile with treatment discontinuation due to AEs in 20% vs 21%. Results were published in The Lancet in Jun 2023

Ref: Takeda | Image: Takeda

Related News:- Takeda Reports Topline Data from P-III (SKYLINE and SKYWAY) Studies of Soticlestat for Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions